|
FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
|
31 October 2017 |
|
FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
|
18 October 2017 |
|
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
|
11 October 2017 |
|
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD
|
25 September 2017 |
|
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab
|
12 September 2017 |
|
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
|
06 September 2017 |
|
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease
|
29 August 2017 |
|
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
|
24 August 2017 |
|
US FDA accepts regulatory submission for acalabrutinib and grants Priority Review
|
02 August 2017 |
|
AstraZeneca and Merck establish strategic oncology collaboration
|
27 July 2017 |